BioTech IP Review

Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and GLP-1 receptor agonist peptides

  • Applicant / Assignee: Pfizer Inc.
  • Patent Application (PCT): PCT/IB2025/050625
  • Publication Number: WO/2025/158284
  • Filing Date: January 22, 2025
  • Publication Date: July 31, 2025
  • Inventors (examples): Robert Gregory Dullea; Kevin James Filipski; others

What It Covers

This international patent application discloses combination therapies that pair:

  • Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists, and
  • Glucagon-like peptide-1 (GLP-1) receptor agonist peptides.

Key elements include:

1. Combination therapeutic compositions:
The application claims pharmaceutical formulations that include specific GIP receptor antagonist compounds together with GLP-1 receptor agonist peptides. These combinations are designed to work synergistically to modulate metabolic pathways.

2. Mechanism of action:
The GIP pathway and GLP-1 signaling are both important in glucose regulation, appetite control, and energy metabolism. By antagonizing GIP receptor activity while activating GLP-1 receptors, the combination therapy aims to enhance weight reduction, improved glycemic control, and better overall metabolic health compared with monotherapy approaches.

3. Methods of use:
The application likely includes methods of treating diseases such as type 2 diabetes, obesity, and related metabolic disorders with these combination regimens — specifying dosing strategies and potentially preferred antagonist/agonist pairs.

4. Pharmaceutical compositions & delivery:
Claims generally cover the formulations, stable compositions, and dosing forms (e.g., injectables) that make such combinations therapeutically viable.

Why This Patent Is Important

• Addresses booming obesity & metabolic therapy markets

Obesity and metabolic dysfunction are among the largest growing therapeutic areas globally, with multi-billion-dollar market potential for drugs that deliver both robust weight loss and durable glycemic control. GLP-1 and dual-agonist therapies have already proven commercial success; a novel combination patent could expand Pfizer’s presence here.

• Potential competitive edge vs. existing therapies

Current marketed drugs (from competitors like Novo Nordisk and Eli Lilly) use GLP-1 and GIP receptor modulation (e.g., dual agonists). Pfizer’s antagonist/agonist combination represents a distinct mechanistic approach that may differentiate its pipeline candidates and claim novel IP space.

• Strategic innovation footprint

Filing a PCT application positions Pfizer to pursue broad global protection for this therapeutic concept. If successful and developed through clinical trials, this IP could underpin blockbuster combination drugs for metabolic disease.

Summary

The WO/2025/158284 patent application from Pfizer protects combination therapies that pair GIP receptor antagonists with GLP-1 receptor agonist peptides for metabolic diseases. This represents a potentially lucrative next-generation therapeutic concept in the obesity and diabetes drug markets — a key strategic priority for Pfizer as it diversifies beyond traditional vaccine and antiviral portfolios.

Leave a comment